Skip to main content

Table 3 Association between PIAS3 fold expression and miRNA-18a fold expression and clinicopathological characteristics of studied patients

From: The role of protein inhibitor of activated STAT3 and miRNA-18a expressions in breast cancer

Variables miRNA-18a
Median (Min–Max)
U/H p value PIAS3
Median (Min–Max)
U/H p value
Age
 > 50 1.7 (0.1–34.5) 53.50 0.202 0.7 (0.0–36.0) U = 75.0 0.936
 ≤ 50 0.6 (0.2–3.6) 0.8 (0.1–12.0)
Focality
 Unifocal 0.7 (0.1–34.5) 20.50 0.807 0.5 (0.0–36.0) U = 13.0 0.373
 Multifocal 2.1 (0.5–3.6) 4.1 (0.9–7.3)
Tumor size
 < 2 cm 0.7 (0.1–34.5) 63.00 0.467 0.8 (0.0–36.0) U = 70.0 0.727
 ≥ 2 cm 1.1 (0.3–17.9) 0.5 (0.1 –13.9)
Histopathological type
 IDC 0.7 (0.1–17.9) 36.00 0.794 0.6 (0.1–36.0) U = 36.0 0.794
 ILC 3.6 0.9
 Others 2.0 (0.3–34.5) 2.5 (0.0–13.9)
Pathological grade
 GI 2.0 (0.3–34.5) 4.758* 0.029* 2.51 (0.0–13.9) H = 2.397 0.302
 GII 0.6 (0.1–6.3) 0.9 (0.1–36.0)
 GIII 3.1 (0.4–17.9) 0.3 (0.1–0.9)
Lymphovascular invasion
 Negative 3.8 (0.3–34.5) 21.500 0.353 0.15 (0.03–13.93) U = 23.0 0.446
 Positive 0.7 (0.1–17.9) 0.84 (0.13–36.0)
LN metastasis
 No 0.6 (0.2–34.5) 74.5 0.852 0.41 (0.03–36.0) U = 67.50 0.574
 Yes 1.1 (0.1–6.3) 0.90 (0.14–33.82)
TNM stage
 0 34.5 1.744 0.418 0 H = 3.008 0.390
 IA 0.5 (0.2–3.8) 0.9 (0.1–36.0)
 IIA + IIB 1.5 (0.2–17.9) 0.8 (0.1–12.0)
 III 0.7 (0.1–3.6) 0.9 (0.1–33.8)
ER
 Positive 0.7 (0.1–34.5) 36.00 0.371 0.8 (0.0–36.0) U = 43.0 0.668
 Negative 1.9 (0.4–5.5) 0.5 (0.1–10.9)
PR
 Positive 0.7 (0.1–34.5) 36.00 0.371 0.8 (0.0–36.0) U = 43.0 0.668
 Negative 1.9 (0.4–5.5) 0.5 (0.1–10.9)
HER2
 Positive 0.9 (0.1–34.5) 49.50 0.974 0.6 (0.0–36.0) U = 48.0 0.921
 Negative 0.7 (0.2–17.9) 1.3 (0.1–7.3)
Molecular type
 Luminal A 0.7 (0.2–17.9) 0.985 0.611 1.3 (0.1–7.3) H = 0.296 0.863
 Luminal B 0.7 (0.1–34.5) 0.8 (0.0–36.0)
 HER2 enriched 1.9 (0.4–5.5) 0.5 (0.1–10.9)
  1. U Mann–Whitney U test which was used to compare between two studied groups, H for Kruskal–Wallis H-test which was used to compare between more than two studied groups, LN lymph node, ER estrogen receptors PR progesterone receptors, HER2 epidermal growth factor receptor 2, TNM tumor-node-metastasis classification system. Min minimum, Max maximum
  2. *Statistically significant at p ≤ 0.05
  3. p value for comparing between the studied groups